Get 15% Off on Memorial Day Sitewide Sale Get 15% Off on Memorial Day Sitewide Sale


The Most Epic Drug Failure. Ever.

Clinical Drug

Story at-a-glance -

  • Bristol-Myers Squibb dropped their new hepatitis C drug – called BMS-986094 – after one clinical trial patient died from heart failure and others were hospitalized with heart and kidney problems
  • The new hepatitis C drug from Bristol-Myers Squibb was much anticipated, but now due to its apparently deadly risks, the drug will be discontinued and the company will take a $1.8-billion charge-off for it
  • Now trials for a separate hepatitis C drug in the same class, this one made by Idenix Pharmaceuticals, have been put on hold as participants have been reporting similar complaints to those suffered with the Bristol-Myers Squibb drug.
  • The newer drugs were supposed to provide an all-oral combination of pills that would cause fewer side effects than current treatments, such as Interferon therapy, which is riddled with serious side effects
  • Natural antioxidant treatment of hepatitis C may be effective, without side effects; up to 25% of cases of chronic hepatitis C also clear up on their own without any treatment

By Dr. Mercola

Only a week after the U.S. Centers for Disease Control and Prevention (CDC) advised all U.S. baby boomers to get tested for hepatitis C because it’s suspected that millions may be infected with it, a drug company with a hepatitis C treatment in the pipeline has suddenly abandoned the drug’s trials.

Read the Full Article for Free!
Subscribe to the #1 Natural Health Newsletter
  • Unlock censored health information that Google doesn't want you to read
  • Keep your privacy secure — We are no longer active on Facebook and will soon be blocking our content from Google search to ensure your privacy stays protected
  • Get access to all of Dr. Mercola's health articles, E-books and special reports

Existing Subscribers: Enter your email address for instant access

You can unsubscribe at any time and I guarantee the privacy of your email. View our privacy policy